|Bid||63.78 x 900|
|Ask||64.07 x 800|
|Day's Range||63.70 - 65.09|
|52 Week Range||60.32 - 79.61|
|Beta (3Y Monthly)||1.22|
|PE Ratio (TTM)||15.29|
|Earnings Date||Apr 29, 2019 - May 3, 2019|
|Forward Dividend & Yield||2.52 (3.90%)|
|1y Target Est||80.43|
Conatus' (CNAT) stock plunges as the phase IIb study on emricasan for the treatment of biopsy-confirmed NASH and liver fibrosis fails.
Investing in biotech stocks has its up days and its down days. For investors in Biogen (NASDAQ:BIIB) -- and more importantly millions of Alzheimer's patients around the world -- yesterday was a down day. On Thursday, Biogen stock plunged more than 30% on the cancelation of stage 3 clinical trials for a blockbuster Alzheimer's medication.Source: Shutterstock The massive drop was truly an unsettling surprise for BIIB shareholders as the drug was seen as a multi-billion blockbuster and game-changing medication for treating the disease. It really did come out of nowhere. The question now is whether to cut bait or fish. Was the drop enough to get investors excited about Biogen stock again?Given its huge revenue drivers, now cheaper price and still large pipeline, the answer is a resounding yes.InvestorPlace - Stock Market News, Stock Advice & Trading Tips What Happened at Biogen?Biotech stocks trade based on expectations. Something positive happens and then investors send the stock skyward and wait for the next big event to occur. It's all about what's coming down the runway. Expectations build upon that. This is true for large biotech stocks as well.For Biogen, the expectation build-up had to do with its Alzheimer's drug candidate aducanumab. The drug was in the class of monoclonal antibody medications. Basically, aducanumab was designed to break down the beta-amyloid plaques that can build up in the brain. These amyloids interfere with communication between brain cells and cause Alzheimer's and mild dementia. Back in 2014, BIIB saw some serious success with aducanumab during an early-stage study. It actually seemed to reduce the build-ups. * 7 Retail Stocks That Will Continue to Rebound in 2019 Thanks to this very positive early trial, Biogen decided to skip over smaller phase 2 studies and move the medication into larger and more advanced stage 3 testing. The idea was that Biogen could skip through the process and land a Food and Drug Administration (FDA) approval much faster. And there was a good chance for that considering how well it did early on.For Biogen stock, this would have been a major win on several fronts.For starters, there have not been any new Alzheimer's therapies approved in more than 15 years. meanwhile, the Alzheimer's Association pegs more than 5.8 million Americans currently living with the disease. Biogen was looking at a potential blockbuster with huge revenue implications. And it potentially needs that revenue to fill the coming declines in its multiple sclerosis portfolio.Unfortunately for BIIB and Alzheimer's patients, they'll have to wait a bit longer.Biogen and its partner Eisai reported that they would discontinue two late-stage trials for the drug after doing a futility analysis. An independent data-monitoring committee came to the conclusion that aducanumab was "unlikely to meet the primary endpoints" in either study.With expectations for the company to score a major blockbuster, investors abandoned Biogen stock. BIIB fell 30% -- or $90 per share -- and had its worst day of trading in nearly 2 decades. Biogen Stock May Be Worth SnaggingBiogen stock's loss was tremendous and goes to show just how much investors were valuing the drug as part of BIIB's future prospects. But perhaps, investors have taken Biogen down too much on the news.For starters, Biogen isn't a fly by night clinical-stage biotech stock. It's just the opposite. The firm has a portfolio of some pretty big blockbusters already. Thanks to winners like Spinraza and Tysabri, BIIB's portfolio managed to see a 10% jump in sales last year to more than $13.45 billion. Moreover, that portfolio managed to generate more than $5.3 billion in free cash flows and impressive earnings.And it's using those profits in a smart way. The key is that Biogen has been building a full pipeline to create a multi-franchise neurology portfolio. This includes its recent buyout of retinal degeneration specialist Nightstar Therapeutics (NASDAQ:NITE). So yes, losing Alzheimer's does stink, but the biotech's rich pipeline and cash flows give it plenty of wiggle room to buy or develop a pipeline. According to CFO Jeff Capello, adding up cash flows, cash on hand and its ability to leverage up and "you get a $37 billion number, which gives us a lot of capacity to add to the business."It's a song and dance we've heard plenty of times before. But Biogen has the firepower to make it work. It can buy a pipeline successfully.For that pipeline potential and drugs already producing revenues, Biogen stock is going for dirt cheap. After yesterday's 30% haircut, you can now snag the biotech firm at just 8.7x free cash flows and a trailing P/E of just 10.50. That's bargain-basement pricing for a biotech leader. For example, Amgen (NASDAQ:AMGN) can be had for a P/E of 14, while Gilead Sciences (NASDAQ:GILD) is closer to 16. Nibbling at Biogen StockGiven the steep drop and perhaps overreaction that sent Biogen stock into extreme value territory, investors with a longer-term timeline may want to consider snagging some of the firm's shares. * 7 Beaten-Up Stocks to Buy as They Reverse Course The lost of the Alzheimer's drug does hurt, but BIIB still has plenty in the tank to get it through. And with today's valuations, there's a decent margin of safety associated with shares. The time to start buying could be now.Disclosure: At the time of writing, Aaron Levitt held a long position in the iShares NASDAQ Biotechnology Index (IBB) -which holds GILD, BIIB and AMGN. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks That Will Continue to Rebound in 2019 * 5 Stocks To Buy for the Happiest Employees * 7 ETFs for a Millennial Portfolio Compare Brokers The post Biogen Stock Fell Too Far on Unfortunate News appeared first on InvestorPlace.
AbbVie (NYSE:ABBV) stock continues to slide, despite a buoyant market. The shares are down 12.3% year-to-date and 28.5% over the past 12 months. That's a dreadful performance in comparison to either the Nasdaq Composite index's 5.22% increase or the 11.8% gain by VanEck Vectors Pharmaceutical ETF (NASDAQ:PPH) from year-ago levels. ABBV stock makes up 5% of the pharma industry exchange-traded fund's current portfolio.Losses continued following AbbVie's latest quarterly report. In it, we saw 2019 guidance fail to excite investors. Several drugs underperformed expectations. However, many investors see the continued weakness in AbbVie stock as an opportunity. The now-5.31% dividend yield in particular has generated much enthusiasm. In this market, that sort of yield is amazing. That is, assuming it comes from a safe source. Should you trust ABBV stock here? AbbVie Stock ConsReplacing Humira: Investors are asking where AbbVie goes after Humira? As of Q4 2018, Humira made up 61% of the company's revenues. Yes, that is down from 65% for the same quarter in 2017, but the company's transition to other products simply isn't happening fast enough to inspire much confidence.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHumira generates about $20 billion in annual sales at the moment and 2018 was another record year for the franchise. However, cracks are showing. International sales -- now getting hit by generics competition -- fell by double digits in 2018. While that was more than offset by a continued rise in U.S. sales, the plaque psoriasis drug should lose American patent protection in 2023. At that point, AbbVie could lose the biggest share of its revenue if other pipeline drugs don't come along fast enough. * Top 7 Service Sector Stocks That Will Pay You to Own Them Political Pressures: The intro of the Trump Administration's proposed 2020 budget has drug prices back in the news. The budget takes aim at drug pricing with a variety of measures. Perhaps most relevant to AbbVie, the budget would sharply cut reimbursements for prescription drugs once a generic hits the market. Given the reliance here on Humira, that's a major concern.Meanwhile, the presidential election cycle is kicking off again. Remember that pharma and biotech stocks got clobbered ahead of the 2016 election as investors considered negative comments from both leading candidates. The Trump administration is going after drug prices, and several of the Democratic candidates seem inclined to do the same. Expect more negative political headlines in coming months.Dividend Cut Coming? Most analyses of AbbVie's dividend safety seem focused almost exclusively on 2019. Yes, the drug maker can afford the ABBV stock 5.5% dividend yield for the time being. In fact, there is plenty of room to spare, based on its relatively low dividend payout ratio.However, so much of the shareholder base here is like that of Gilead Sciences (NASDAQ:GILD) in 2015. That is to say, investors were attracted to past rising profits and oblivious to future threats. Just as Gilead's profits plummeted once HCV revenue started dropping, AbbVie will face a far more-complicated situation in a few years. People buying AbbVie for its past dividend history are driving while looking out the rearview mirror. AbbVie Stock ProsThat Dividend Yield: Just as any bearish argument involving ABBV stock starts with Humira's patent problems, bulls invariably point to the dividend yield. And with good reason. At this point, ABBV stock is offering investors a choice yield of 5.31%. You'll find only a handful of other $100-billion market cap companies that pay as much.On top of that, AbbVie continues to increase its dividend. In the past year, it upped its quarterly payout from 96 cents to $1.07. Sure, there is good reason to doubt that the dividend hikes will continue once Humira goes off patent. But for income investors that are willing to play the timing game, there should be a few good years of income potential here as Humira enjoys its waning years of windfall sales numbers. * 5 Cloud Stocks to Help Your Portfolio Fly New And Rising Drugs: AbbVie has a lot of newly launching or still-growing drugs moving to replace Humira. Analysts have suggested that AbbVie could hit $7 billion peak sales with Imbruvica, and reach the $1-2 billion range for each of three others, Venclexta, Orlissa, and Mayvret. Meanwhile, while Risankizumab and Upadacitinib are still a distance from commercial success, both are potentially $5 billion drugs if all goes according to plan.Add it all up, and you could match Humira's current $20 billion annual sales contribution with this assortment of newer drugs. It would take a lot to go right -- and in pharma, things usually don't all follow plan -- but there is a path here. It's also worth remembering that Humira sales won't go straight to zero even as the generics arrive; there will be several more years of reasonably strong cash flows first.AbbVie still has a respectable pipeline and some time to keep developing other options even as Humira's U.S. patent cliff steadily approaches.Discounted Stock: Despite a hot stock market, ABBV shares have been caught in a downdraft. With the stock market up 15% for the year, AbbVie's 13% decline stands in a rather stark contrast.Given the decline, the stock is now trading at under 9x forward earnings. I don't think P/E multiples are a great metric for pharma companies due to patent issues. But plenty of other investors do. The combination of a low P/E ratio and a stock that has fallen sharply will likely attract numerous dip buyers to help give ABBV stock a bounce. AbbVie Stock VerdictThe clock is ticking. In 2023, Humira's U.S. sales are likely to start to plunge as generic competition arrives. As we've seen internationally, Humira sales started to tank as soon as that happen elsewhere. Will the company's newly launched drugs and pipeline do enough to replace Humira?My guess that it won't be. Humira did $19.9 billion in sales last year. A typical blockbuster drug will hit a few billion a year in sales. AbbVie needs multiple new blockbusters simply to maintain its current revenue stream, let alone grow additionally. It's not impossible, but the odds are long. Unfortunately, $30 billion-plus in debt limits AbbVie's options and makes a dividend cut in coming years quite likely. That will be terrible news for ABBV stock, given its huge dividend income investor base.At the time of this writing, Ian Bezek owned GILD stock. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Invincible Stocks Leading The Bull Market Higher * 5 Dow Jones Stocks Coming to Life * 7 of the Best High-Yield Funds for 2019 and Beyond Compare Brokers The post Does Recent Weakness in AbbVie Stock Make It a Buy? 3 Pros, 3 Cons appeared first on InvestorPlace.
Gilead Sciences Inc NASDAQ/NGS:GILDView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for GILD with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting GILD. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding GILD are favorable, with net inflows of $14.03 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
An activist investor wants to know what drug giant Gilead is doing with its multibillion-dollar windfall from the 2017 federal tax overhaul.
Piper Jaffray notes that the price increases were about 30% lower than what previous hikes have been and were well below price increases that other companies have implemented.
Gilead paid its departed president and CEO nearly $25 million last year, but that figure is nuanced with one-time changes to his stock-based compensation.
Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.
Gilead Sciences (GILD) closed the most recent trading day at $65.75, moving +1.42% from the previous trading session.
Gilead Sciences Inc. (GILD), CVS Health Corp. (CVS), Walgreens Boots Alliance Inc. (WBA) and Vodafone Group PLC (VOD) have declined to their three-year lows. The price of Gilead Sciences Inc. (GILD) shares declined to $63.23 on March 8, which is 4.6% above the three-year low of $60.32. Gilead Sciences is an American international pharmaceutical and biotechnology company that develops and commercializes therapeutics.
On paper, pharmaceutical giant Gilead Sciences (NASDAQ:GILD) is off to a solid start this year. So far in 2019, GILD stock is up over 4%. While that's not very impressive, GILD also pays out a 3.9% dividend. So in total, the owners of Gilead stock should receive healthy, double-digit-percentage returns in 2019.Source: Shutterstock Of course, that assumes that Gilead stock will continue to rise. But after examining the situation more closely, that appears to be unlikely. Since early February, GILD has fallen 8%. Moreover, Gilead stock has formed a bearish trend channel since October of last year. Making matters worse, the GILD bulls seemingly have no argument that can stop the decline of GILD stock. * 5 Airline Stocks In Serious Trouble As if stakeholders needed any more bad news, the company's fourth-quarter earnings per share came in below expectations. Against analysts' consensus earnings per share estimate of $1.74, GILD meekly delivered $1.44. Conspicuously, its Q4 EPS dropped 19% year-over-year.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe revenue picture wasn't that much better for GILD stock. Sure, the company beat out the consensus estimate, which called for $5.52 billion, with a $5.8 billion haul. Unfortunately, the sales beat was overshadowed by the fact that the company's revenue fell nearly 3% versus the year-ago quarter.Most painful of all were product sales, which also slipped 3% YoY, to $5.68 billion. In particular, the revenue of Gilead's hepatitis C drugs tumbled 51% YoY to $738 million.Pouring salt on a festering wound, the company's hepatitis B treatments fell by double-digit-percentage levels, declining to $797 million. Unsurprisingly, Gilead stock tumbled after the earnings report.But what's truly worrisome about GILD is that after more than a month,Gilead stock still hasn't recovered. With Gilead's new CEO, Daniel O'Day, at the helm, should investors hold onto GILD stock, or sell their shares? GILD Stock Has Priced in the Bad NewsI don't blame shareholders for feeling jittery. Although O'Day has a strong, relevant track record given his time at Roche (OTCMKTS:RHHBY), he's in an unenviable situation. To prevent further damage to Gilead stock, the new leader must address the fallout from the large decline of the company's hepatitis C revenue, as well as diversify his company's product lineup.This is much easier said than done. A key reason why the markets punished GILD stock was that the company was essentially too successful. To put it bluntly, pharmaceuticals have almost no incentive to cure diseases. Instead, managing them and making victims of the disease continuously obtain the drugs will guarantee recurring income.Gilead took a radically-different approach. Rather than manage hepatitis C, its Sovaldi drug cured the disease. That seemed like a bad business move, considering that rival AbbVie (NYSE:ABBV) has a similar drug. The key difference between the treatments is that AbbVie's offering is ineffective, but profitable.Indeed, when you look at Gilead's Q4 results, you can't help but second-guess its management. Nevertheless, I don't think giving up on GILD stock is necessarily the right answer.Although the company has steep challenges ahead, I'm encouraged by the relatively modest volatility of GILD stock. Since Q4, Gilead stock is down 8%. That's a significant decline, but it's not devastating, particularly because GILD's key money maker appears to have weakened so much.Moreover, I find it interesting that GILD stock is staying above its long-term support line that extends back to 2013. Again, if Gilead has really incurred anything close to a fatal blow, it's not showing up in the charts.Secondly, the Q4 report demonstrated that the company has the potential to turn things around. The revenue of its HIV treatments -- including Biktarvy which demonstrates strong potential -- grew meaningfully, gaining 21% to $4.1 billion. Also, its immunotherapy cancer drug, Yescarta, raked in $264 million in 2018. The Long-term Outlook of Gilead Stock Is PositiveIf you look at the GILD stock price over the last five years, and compare it to the progression of the company's top line, you'll notice that they generally align with each other. After absorbing some tough spills, Gilead has generated meaningful momentum with its new-drug pipeline. Eventually, Gilead's share price will likely rebound as wellMore importantly, I think that management's decision to find effective cures for diseases was correct. Although Gilead stock is taking some hits due to the loss of revenue from its hepatitis C treatment, the drug proved that Gilead's science actually works. In the long run, that's an invaluable (and exclusive) brand message that GILD can exploit.And what about AbbVie's hepatitis C drug that manages the illness? ABBV may have outperformed GILD in the past, but today, it's in a worse situation. So far this year, ABBV is down more than 12%.In other words, within the broader healthcare industry, the science eventually matters. While GILD stock isn't perfect, I have confidence that this proven company can work out its pipeline issues. The same can't be said for the competitors that merely tow the line.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dividend Stocks Already Rewarding Shareholders In 2019 * The 10 Best-Performing ETFs This Year * 7 Stocks That Should Be Worried About a Data Dividend Compare Brokers The post Donat Abandon Gilead Stock After Weak Q4 Results appeared first on InvestorPlace.
Gilead Sciences, Inc. (GILD) today announced findings from two studies that support the further development of GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid function, for potential future use as part of long-acting HIV combination therapy. Interim blinded data from a Phase 1 study in healthy trial participants demonstrated that single doses of GS-6207 of up to 450 mg, administered subcutaneously, achieved sustained concentration levels and were well-tolerated. Separately, in vitro data demonstrated picomolar potency with GS-6207, including against HIV strains resistant to other antiretroviral (ARV) classes.
[Editor's note: This story was originally published in December 2018. It has since been updated and republished, but the author's position may have shifted since its last publication.]Any cursory look at the markets would reveal that 2018 wasn't the best year for investors. That goes for speculative assets as well, including marijuana stocks. Although going green has proven net positive for the early birds, the sector tanked heavily during the October selloff. Still, I wouldn't drop them from your list of stocks to buy just yet.Despite their well-publicized fall from grace, several marijuana stocks have stabilized from their severe correction. While that's no guarantee that the industry is done spilling blood, the deflated prices will almost certainly attract speculators. Should enough risk-takers enter the arena, publicly traded cannabis companies will jump higher, even if it's only a temporary swing.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHowever, some other factors suggest that marijuana stocks may enjoy a sustained rise. First, none of the big waves currently spooking benchmark indices affect the legal cannabis industry. Whether it's political unrest in the Middle East, the spiraling protests in Paris or the ugly Huawei controversy, marijuana, for now, is mostly a North American issue.Second, medical cannabis, on the one hand, potentially offers significant social utility. A stunning Bloomberg article analyzed whether Gilead Sciences (NASDAQ:GILD) made the right business decision in producing a drug that cured diseases rather than managing them. The perception exists that big pharma companies should focus primarily focus on revenue generation rather than medical breakthroughs.On the other hand, medical marijuana companies have no such quandaries. Because they are typically much smaller outfits, they don't mind the inability to patent a naturally occurring plant. If anything, an organization that produces a proven, effective cannabis strain would represent a buyout target. This asymmetry challenges Big Pharma, but makes marijuana-based pharmaceuticals among the best stocks to buy. * 9 Trade War Stocks to Sell on U.S.-China Deal News While the sector remains risky, the deflated market environment offers attractive deals on these 10 marijuana stocks. Tilray (TLRY)Tilray (NASDAQ:TLRY) easily represents the most interesting and controversial picks among marijuana stocks to buy for next year. Within a few months after its initial public offering, TLRY stock pulled a ten-bagger. But as you know, the victory was short-lived, and Tilray came crashing down to earth.Naturally, several analysts and commentators blasted the company as an unsustainable bubble. Keep in mind, though, that since its IPO, TLRY stock is up over 470%. I wouldn't dismiss such a performance as a failure. Moreover, shares have stabilized near the $100 level. If this company was as terrible as the bears claimed, I doubt TLRY would ride this support line.Now, it's easy to dismiss any individual opinion. It's much harder when a banking giant like Barclays (NYSE:BCS) increases their position. Clearly, they view TLRY as one of the best stocks to buy in 2019, and they're putting their money where their mouth is. Canopy Growth (CGC)The prior two months have not been for Canopy Growth (NYSE:CGC). Taking a similar route to most other marijuana stocks, CGC dropped 26% in October. The following November appeared promising, building off a sharp burst of momentum. Unfortunately, the rally lost traction and CGC ended up losing double-digits for the month.But what I like about Canopy Growth is that true to its name, it's a steady grower. Despite the recent sharp losses, its longer-term bullish trend channel remains intact. I wouldn't consider hitting the panic button unless shares started to decisively fall below the $25 level. That said, I think the broader fundamentals favor CGC stock. * 10 High-Yield Monthly Dividend Stocks Tilray has a financial institution backing it. For Canopy Growth, they have alcoholic-beverages maker Constellation Brands (NYSE:STZ). This is a trend that investors, even the skeptical ones, shouldn't ignore. Big money is increasingly stepping into the cannabis sector, making CGC one of the best stocks to buy despite its well-publicized setbacks. Cronos Group (CRON)While most marijuana stocks have struggled to rekindle their prior catalysts, Cronos Group (NASDAQ:CRON) currently stands above the competition. For the month so far, CRON stock has streaked to an amazing 39% lead. Of course, most of that optimism comes courtesy of Altria Group (NYSE:MO).The iconic tobacco company made headlines when it announced a partnership with Cronos. The deal, worth $1.8 billion, provides CRON with a boatload of cash to further develop its cannabinoid (CBD) products. On the other side of the fence, Altria needs something fresh to reinvigorate its traditional tobacco business.A key long-term synergy could be the vaporizer market. Vaping CBD e-liquids have taken off in terms of popularity. Altria has attempted to break into the vaporizer market with its own heat-not-burn tobacco products. But with Cronos' expertise in CBD, Altria has another angle in this sector to work.In the meantime, feel free to put CRON in your list of best stocks to buy for next year. Aurora Cannabis (ACB)Aurora Cannabis (NYSE:ACB) has suffered a disjointed long-term performance in the markets, even compared to other marijuana stocks. In 2017, ACB stock shot from near-obscurity to the toast of Wall Street. This year, ACB has shown flashes of brilliance, but little to show for it overall.I expect the cannabis sector to wake from its slumber. When it does, the currently embattled ACB has the potential to become one of the best stocks to buy for 2019. The markets really haven't responded positively to Aurora's buyout of Farmacias Magistrales. Farmacias made news when it became the first, and so far only Mexican importer of raw materials that contain the psychoactive component THC. * 7 Dividend Stocks Already Rewarding Shareholders In 2019 The buyout allows Aurora a viable channel to Latin America's medical-marijuana market. In addition to Farmacias, ACB has operations in Colombia and Uruguay. Should the industry establish medical breakthroughs in Latin America, advocates will pressure the U.S. to further loosen federal cannabis restrictions. Auxly Cannabis (CBWTF)One of the most common misconceptions is that legal-cannabis advocates are only "fronting" to get high. While that use is unavoidable, the botanical industry has several legitimate applications. On the business aspect, several investors assume that all cannabis companies focus on growing weed.But as Auxly Cannabis (OTCMKTS:CBWTF) demonstrates, marijuana stocks feature the same vibrancy and dynamism as other commodity related investments. Auxly specializes in all areas of the legal-cannabis supply chain, with a primary focus on upstream operations. This involves partnering with companies that grow the actual product.In addition, CBWTF levers a viable midstream operation. This includes activities such as extraction, processing and branding. It also involves longer-term efforts like research and development.The biggest advantage for CBWTF to pull this streaming business off is its balance sheet. With a favorable cash-to-debt ratio, Auxly can make key acquisitions and investments while the cannabis market is still young. Origin House (ORHOF)Formerly known as CannaRoyalty, Origin House (OTCMKTS:ORHOF) is another cannabis firm that made its name through streaming businesses. And while it still generates some revenue through its initial line of work, ORHOF has become a powerhouse in branding.The proof is in its utter domination of California. Unbeknownst to me prior to this write-up, the Golden State is the world's largest legal cannabis market. With a title like that, it's a wonder how anything gets done around here. Joking aside, Origin House boasts more than 450 California-based dispensaries and more than 50 popular brands. * 7 Emerging Market Stocks to Buy on This Dip In other words, if you can make it in California, you can make it anywhere. This bodes very well for ORHOF stock. Last month's midterm elections proved that legal weed is gaining serious momentum. Inevitably, more recreational markets will open, allowing Origin House to expand its dominating presence. Marimed (MRMD)Let's face facts: Marijuana stocks don't exactly have the greatest reputation for stability. That goes five-fold for over-the-counter offerings. One notable exception to this rule is Marimed (OTCMKTS:MRMD).While other sector players hemorrhaged severely during the October rout, MRMD stock actually enjoyed a standout performance, gaining nearly 19%. That said, Marimed eventually gave up those gains and then some. Since the first of November, MRMD is down a little over 17%.Still, I think it's fair to say that compared against other marijuana stocks to buy, Marimed has held up well. Heading into the new year, MRMD has the potential to turn heads.Its biggest advantage is its highly demanded consultation services. Covering everything from licensing application support to facilities management, MRMD provides relevant and critical insights for budding entrepreneurs. Plus in my opinion, Marimed levers one of the brightest and well-rounded leadership teams in the marijuana industry. Medmen Enterprises (MMNFF)Marijuana retail outfit Medmen Enterprises (OTCMKTS:MMNFF) suddenly became one of the best stocks to buy in botany around mid-October. Within a matter of days, MMNFF stock skyrocketed over 60%. But like most over-the-counter affairs, Medmen gave up its profits just as quickly.Since its peak closing price, MMNFF stock has dropped a humbling 53%. I get that most investors will balk at such volatility. However, for the speculator, I sense serious growth opportunities for Medmen.The company has established itself as a retailer of premium cannabis products. Yet many investors may not appreciate that Medmen is a vertically integrated organization. From its upstream production operation down to extraction, branding and distribution, Medmen essentially controls its supply chain. This is a "farm-to-bong" business at its finest. * 5 Cheap ETFs Worth Considering As Medmen CEO Adam Bierman stated recently, this structure affords the company generous margin-expansion possibilities. Further, the aforementioned high-profile deals only help validate smaller players like MMNFF stock. Aleafia Health (ALEAF)Broader and sector weakness has hurt virtually all marijuana stocks. However, the lesser-known names have experienced disproportionate pain. Unfortunately, this is something that Canadian cannabis firm Aleafia Health (OTCMKTS:ALEAF) knows all too well.But despite its severe market loss over the past two-and-a-half months, ALEAF stock offers a speculative opportunity for risk-takers. For starters, the underlying company features the largest network of referral-only medical cannabis clinics in Canada. Furthermore, their patient base continues to increase as the industry gains social recognition and acceptance.Management has also invested heavily in cultivation facilities, targeting an annual growing capacity of 98,000 kilograms in 2019. Most importantly, Aleafia has the substance to back up the outlook. In its most recent third-quarter earnings report, the company increased revenue 36% year-over-year. Diego Pellicer Worldwide (DPWW)We've arrived at the end of our journey regarding marijuana stocks to buy in 2019. In keeping with my loose tradition, I like to throw in an extremely speculative name. And don't roll your eyes at me: you know you want to know!The following idea comes from an InvestorPlace reader named Anthony. He asked my opinion regarding Diego Pellicer Worldwide (OTCMKTS:DPWW). My answer to him is the same one I'm giving to you, which is that DPWW stock is extremely risky. Aside from its distressingly low trading volume and market capitalization, Diego Pellicer lacks financial strength to convincingly pull off its licensing and royalties business model.However, I'm intrigued with its premium branding business. Not that I would know, but Diego Pellicer specializes in high-class cannabis products. As companies like Origin House and Medmen have proven, cannabis users eschew quantity for quality. That could lead to a surprising turnaround for DPWW stock. * 3 Market-Leading Stocks to Buy With Red on the Street Or you can lose every cent that you put in.As of this writing, Josh Enomoto is long MRMD and ALEAF. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks That Should Be Worried About a Data Dividend * 5 Cheap ETFs Worth Considering * 7 Cheap Stocks Under $5 That Could Soar Compare Brokers The post 10 Top Pot Stocks 2019 Has to Offer appeared first on InvestorPlace.
Gilead Sciences, Inc. today announced data from two studies evaluating the resistance profile of Biktarvy® in virologically suppressed adults switching from dolutegravir/abacavir/lamivudine or a boosted protease inhibitor -based regimen for the treatment of HIV-1.
Gilead Sciences, Inc. (GILD) today announced 48-week results from a Phase 2/3 study (Study GS-US-380-1474) evaluating the efficacy and safety of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, BIC/FTC/TAF), a once-daily single tablet regimen, in virologically suppressed adolescents and children at least 6 years of age who are living with HIV. Through Week 48, Biktarvy maintained high rates of virologic suppression with a low incidence of study drug-related adverse events and no treatment-emergent resistance. “These findings indicate that Biktarvy, an oral single-tablet regimen that can be taken with or without food, has the potential to be an effective and well-tolerated treatment option for some children and adolescents living with HIV,” said Aditya H. Gaur, MD, Clinical Director, Department of Infectious Diseases at St. Jude Children’s Research Hospital and lead study investigator.